IVA - Inventiva Sa logo

Inventiva Sa

IVA

Inventiva S.A. develops oral small molecule therapies primarily for metabolic dysfunction-associated steatohepatitis and mucopolysaccharidoses. Its key products include Lanifibranor, in Phase 3 trials, and Odiparcil for treating specific genetic disorders.

⚕️ Healthcare NASDAQ Listed 2020 € EUR
$1,000 invested 5 years ago →$261today

Score Overview

1 Year
Score
Net Growth-76.43%
Net TrendShrank
Net Income Consistency—
Rev Growth1.09%
Rev TrendGrew
Revenue Consistency—
5 Years
Score1.5
Net Growth-10x
Net TrendNever
Net Income Consistency—
Rev Growth8.06%
Rev Trend60%
Revenue Consistency—
All Time
Score
Net Growth-16x
Net TrendNever
Net Income Consistency
Rev Growth12x
Rev Trend67%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Inventiva Sa has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. IVA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 3.71—
1 Year2025-10-23
$ 5.87-36.80%
5 Years2021-10-22
$ 14.24-73.95%
All Time2020-07-10
$ 13.42-72.35%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in EUR

Year
TTM€ 4M-€ 600M
2025€ 4M-€ 340M€ 99M
2024€ 9M-€ 184M€ 96M
2023€ 17M-€ 110M€ 27M
2022€ 12M-€ 54M€ 87M
2021€ 4M-€ 49M€ 86M
IPO2020€ 372K-€ 31M€ 113M
IVA - Inventiva Sa logo

Inventiva Sa fundamental performance

Across Inventiva Sa's full reported history, from 2020 to 2025, revenue grew from € 372K to € 4M and net income went from -€ 31M to -€ 340M. Revenue increased in 67% of the years measured; net income in 0%.

Inventiva Sa currently holds a 5-year HDB Score of 1.5 out of 10. How the HDB Score is calculated.

Membership

Explore IVA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies